Global Health Clinics (MJRX) AI Stock Analysis

• Market Cap: C$516.57K
• Dividend Yield: N/A
• Average Volume (3M): 7.79K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.43
• Revenue Growth: -42.42%
• EPS Growth: -17.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 9,392,138
• 10 Day Avg. Volume: 900
• 30 Day Avg. Volume: 7,790
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.02
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.05 ▲(170.00% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held down by very weak financial performance—shrinking revenue, deeply negative margins, ongoing cash burn, and a highly stressed balance sheet with negative equity and rising debt. Technicals provide partial offset with the stock trading above major moving averages, but mixed momentum indicators limit the boost. Valuation remains challenged due to negative earnings and no dividend yield data.

Positive Factors

Industry Position

Operating in specialty and generic pharmaceuticals provides durable structural demand, regulatory-driven barriers to entry, and recurring need for medicines. These industry characteristics support long-term revenue opportunities if the company stabilizes operations and secures product-market fit.

Cash-earnings Alignment

FCF and net income moving together indicates losses are cash-based rather than large non-cash accounting items. That transparency reduces risk of hidden deterioration and means operational improvements would likely convert to real cash flow, enabling durable recovery potential.

Early FCF Improvement

Reported modest positive free cash flow growth suggests initial traction on controlling outflows. If sustained, even gradual FCF improvement can compound, reducing refinancing pressure and providing a runway for restructuring or reinvestment over the next several quarters.

Negative Factors

Shrinking Revenue

A multi-year pattern of materially shrinking revenue weakens scalability and erodes the fixed-cost absorption needed to reach profitability. Continued declines constrain cash generation and make it harder to finance R&D, regulatory steps, or sales investments required for durable recovery.

Highly Stressed Balance Sheet

Sustained negative equity with rising debt and a tiny asset base creates elevated solvency and refinancing risk. This structural imbalance limits strategic flexibility, increases dilution or creditor constraints, and raises the probability of forced capital raises or restructuring over months.

Ongoing Cash Burn

Persistent negative operating and free cash flow at material levels creates continuous financing needs. Without sustained revenue recovery or cost restructuring, ongoing burn will drive repeated capital raises or creditor pressure, impairing long-term investment and execution capacity.

Global Health Clinics Business Overview & Revenue Model

Company Description

Global Health Clinics Ltd. operates in the cannabis industry. The company operates medical clinics, which guide patients through the process of becoming legal users of marijuana. It also engages in developing psilocybin products for research and usage for pharmaceutical purposes. The company was formerly known as Leo Resources Inc. and changed its name to Global Health Clinics Ltd. in August 2018. Global Health Clinics Ltd. was incorporated in 2013 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Global Health Clinics Financial Statement Overview

Summary

Financials are very weak: TTM revenue declined 35.9% to 30.6k, gross profit is negative, and profitability remains deeply negative (TTM net margin ~-43%). Cash flow is also negative (TTM operating cash flow and free cash flow ~-584k). The balance sheet is the biggest risk with sustained negative equity (~-4.9M) alongside rising debt (~2.1M) and a very small asset base (~66k), implying elevated solvency/refinancing and dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue fell to 30.6k (down 35.9%), continuing a multi-year pattern of shrinking sales. Profitability is very weak: gross profit is negative in TTM (and also negative in the latest annual period), and operating and net margins are deeply negative, with TTM net margin around -43%. Losses remain large relative to the revenue base, indicating the business has not found a scalable cost structure yet.

Balance Sheet

The balance sheet is highly stressed with consistently negative shareholders’ equity (about -4.9M in TTM), which is a major solvency red flag. Debt has climbed over time (to ~2.1M in TTM) while total assets are very small (~66k), implying a thin asset base versus obligations. While the debt-to-equity ratio is shown as negative due to negative equity, the underlying takeaway is elevated financial risk and limited balance-sheet flexibility.

Cash Flow

Cash generation remains negative: TTM operating cash flow and free cash flow are both about -584k, indicating ongoing cash burn. A modest positive TTM free cash flow growth is not enough to change the picture given persistent outflows. A relative positive is that free cash flow and net income track closely (both negative), suggesting losses are broadly reflected in cash results rather than being driven by one-time accounting effects.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	47.77K	82.96K	102.85K	146.81K	225.09K
Gross Profit	-515.73K	63.88K	80.64K	116.00K	177.75K
EBITDA	-1.05M	-947.00K	-1.57M	-1.35M	-8.34M
Net Income	-1.27M	-1.08M	-1.63M	-1.37M	-8.48M
Balance Sheet
Total Assets	66.14K	29.33K	241.50K	578.81K	610.60K
Cash, Cash Equivalents and Short-Term Investments	50.48K	9.19K	214.34K	496.69K	456.26K
Total Debt	1.91M	1.52M	1.10M	322.31K	30.81K
Total Liabilities	4.59M	3.29M	2.43M	1.14M	1.05M
Stockholders Equity	-4.53M	-3.26M	-2.18M	-559.58K	-440.39K
Cash Flow
Free Cash Flow	-572.21K	-496.55K	-1.01M	-1.49M	-825.80K
Operating Cash Flow	-572.21K	-496.55K	-1.01M	-1.49M	-825.80K
Investing Cash Flow	0.00	0.00	0.00	0.00	428.97K
Financing Cash Flow	613.50K	291.40K	727.48K	1.53M	763.22K

Global Health Clinics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MJRX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.04, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.81 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MJRX.

Global Health Clinics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GTII	65 Neutral	C$2.06B	16.23	6.29%	―	6.18%	-28.69%
DHT.UN	58 Neutral	C$928.04M	-9.05	-10.92%	3.56%	-0.94%	-540.90%
TRUL	56 Neutral	$1.67B	-13.95	-9.71%	―	4.27%	3.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CURA	50 Neutral	C$2.44B	-8.05	-28.58%	―	-3.38%	-31.35%
VRNO	48 Neutral	C$2.17B	-1.75	-30.10%	―	-4.58%	-141.91%
MJRX	47 Neutral	C$516.57K	-0.28	―	―	-42.42%	-17.33%